Pathogenesis of hepatic steatosis and fibrosis: Role of leptin
Research output: Chapter in Book/Report/Conference proceeding › Book chapter › Research › peer-review
Standard
Pathogenesis of hepatic steatosis and fibrosis: Role of leptin. / Magkos, Faidon; Fabbrini, Elisa; Klein, Samuel.
Leptin: Regulation and Clinical Applications. ed. / Sam Dagogo-Jack. Memphis, TN : Springer, 2015. p. 89-101.Research output: Chapter in Book/Report/Conference proceeding › Book chapter › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - CHAP
T1 - Pathogenesis of hepatic steatosis and fibrosis: Role of leptin
AU - Magkos, Faidon
AU - Fabbrini, Elisa
AU - Klein, Samuel
N1 - Publisher Copyright: © Springer International Publishing Switzerland 2015.
PY - 2015
Y1 - 2015
N2 - Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver abnormalities, ranging from simple steatosis, to steatohepatitis and cirrhosis, in the absence of “excessive” alcohol consumption or any other identifiable cause(s) for liver disease [1]. Histologically, NAFLD can be categorized into: (1) simple steatosis in the absence of hepatocellular injury (nonalcoholic fatty liver, NAFL); and (2) steatohepatitis (nonalcoholic steatohepatitis, NASH), characterized by the presence of steatosis and inflammation with hepatic injury (ballooning), with or without fibrosis [1]. NASH can progress to cirrhosis, liver failure, and rarely liver cancer, whereas the progression to more severe forms of liver disease is minimal in patients with NAFL. Steatosis is the hallmark of NAFL and NAFLD and can be defined chemically, when intrahepatic triglyceride (IHTG) content exceeds 5 % of liver volume or liver weight [2], histologically, when 5 % of hepatocytes contain visible intracellular triglyceride [3], and radiologically, by using magnetic resonance spectroscopy (MRS) [4]. The results from one study in subjects who were considered to be at low-risk for NAFLD (i.e., normal weight, normal fasting serum glucose and alanine aminotransferase concentrations, and absence of diabetes) indicate an upper “normal” amount of IHTG of 5.6 % of liver volume, which represented the 95th percentile in this population [5]. Data from another study found the 95th percentile for IHTG content was 3 % in young lean subjects with normal oral glucose tolerance [6].
AB - Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver abnormalities, ranging from simple steatosis, to steatohepatitis and cirrhosis, in the absence of “excessive” alcohol consumption or any other identifiable cause(s) for liver disease [1]. Histologically, NAFLD can be categorized into: (1) simple steatosis in the absence of hepatocellular injury (nonalcoholic fatty liver, NAFL); and (2) steatohepatitis (nonalcoholic steatohepatitis, NASH), characterized by the presence of steatosis and inflammation with hepatic injury (ballooning), with or without fibrosis [1]. NASH can progress to cirrhosis, liver failure, and rarely liver cancer, whereas the progression to more severe forms of liver disease is minimal in patients with NAFL. Steatosis is the hallmark of NAFL and NAFLD and can be defined chemically, when intrahepatic triglyceride (IHTG) content exceeds 5 % of liver volume or liver weight [2], histologically, when 5 % of hepatocytes contain visible intracellular triglyceride [3], and radiologically, by using magnetic resonance spectroscopy (MRS) [4]. The results from one study in subjects who were considered to be at low-risk for NAFLD (i.e., normal weight, normal fasting serum glucose and alanine aminotransferase concentrations, and absence of diabetes) indicate an upper “normal” amount of IHTG of 5.6 % of liver volume, which represented the 95th percentile in this population [5]. Data from another study found the 95th percentile for IHTG content was 3 % in young lean subjects with normal oral glucose tolerance [6].
U2 - 10.1007/978-3-319-09915-6_8
DO - 10.1007/978-3-319-09915-6_8
M3 - Book chapter
AN - SCOPUS:84944596184
SN - 9783319099149
SP - 89
EP - 101
BT - Leptin
A2 - Dagogo-Jack, Sam
PB - Springer
CY - Memphis, TN
ER -
ID: 302380559